Fig. 3From: A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemiaPlasma concentration BEZ235 day 15. Plasma concentrations of BEZ 235 at day 15 showing again a broad interpatient variability. BEZ 235 concentrations did not correlate with response to treatmentBack to article page